WASHINGTON -- Darolutamide (Nubeqa) plus androgen deprivation therapy (ADT) significantly improved outcomes compared with ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC), ...
Secondary endpoints were overall survival (OS), time to metastatic castration-resistant prostate cancer (mCRPC), radiological PFS (rPFS; based on imaging frequency as clinically indicated), PSA <0.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results